Moyed Alsaadawe | Oncology | Innovative Research Award

Published on by Applied Scientist

Innovative Research Award

Moyed Alsaadawe
Southern Medical University, Iraq

Moyed Alsaadawe
Affiliation Southern Medical University
Country Iraq
Scopus ID 57208672195
Documents 12
Citations 407
h-index 6
Subject Area Oncology
Event Applied Scientist Awards
ORCID 0000-0001-5594-5480

Moyed Alsaadawe is a PhD student candidate at Southern Medical University with research interests spanning molecular biology, genetics, cell biology, virology, oncology, and biochemistry. His scholarly activities emphasize the molecular mechanisms of disease, viral pathogenesis, and cancer development. His publication record includes investigations into the relationship between viral infections and malignancy, reflecting an interdisciplinary approach to biomedical science.[1]

Abstract

Moyed Alsaadawe in relation to the Innovative Research Award. His work integrates molecular biology, genetics, virology, and oncology with an emphasis on understanding disease mechanisms and cancer development. His published research demonstrates interest in translational biomedical science and interdisciplinary collaboration while contributing to contemporary discussions concerning virus-associated malignancies.[2]

Keywords

Cell Biology; Molecular Biology; Genetics; Oncology; Virology; Biochemistry; Cancer Biology; Epstein–Barr Virus; COVID-19; Translational Medicine.

Introduction

Research at the interface of molecular biology and oncology has become increasingly important for understanding cancer initiation, progression, and therapeutic intervention. Investigations involving viral infections, immune responses, and genetic regulation provide valuable insights into disease mechanisms. Dr. Alsaadawe’s academic interests align with these contemporary scientific priorities through studies emphasizing molecular pathways and virus-associated cancers.[3]

Research Profile

Moyed Alsaadawe is affiliated with Southern Medical University and has developed a research profile centered on molecular mechanisms underlying disease. His interests encompass cell biology, virology, molecular genetics, oncology, and biochemical pathways. According to the supplied publication metrics, his scholarly record includes 12 indexed documents, 407 citations, and an h-index of 6, indicating measurable academic engagement within biomedical research.[1]

Research Contributions

  • Investigation of molecular mechanisms associated with cancer biology.
  • Research on virology and virus-associated malignancies.
  • Integration of molecular biology and genetics into translational biomedical research.
  • Contribution to interdisciplinary oncology research concerning Epstein–Barr virus and COVID-19.

Publications

  • From Viral Infection to Malignancy: The Dual Threat of EBV and COVID-19 in Cancer Development.
    Viruses, published 30 August 2025.

Research Impact

The available publication metrics indicate continued scholarly activity in biomedical sciences with research outputs addressing clinically relevant molecular mechanisms. Citation performance reflects recognition of published work within the scientific community while ongoing doctoral research may contribute further to the understanding of cancer biology and infectious disease interactions.[4]

Award Suitability

Moyed Alsaadawe demonstrates characteristics commonly considered during evaluations for research recognition. Suitability for the Innovative Research Award would ultimately depend upon the formal assessment criteria established by the Applied Scientist Awards committee, including originality, scientific quality, research impact, and eligibility requirements.[5]

Conclusion

Moyed Alsaadawe’s academic activities illustrate an interdisciplinary focus on molecular biology, virology, genetics, and oncology. His published research concerning virus-associated cancer development contributes to ongoing scientific discussions in biomedical research. Continued investigation in these areas may further strengthen his scholarly profile and support future research collaborations and recognition.

References

  1. Elsevier. (n.d.). Scopus author details: Dr. Moyed Alsaadawe, Author ID 57208672195. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57208672195
  2. Moyed Alsaadawe., et al. (2025). Microbiome-Driven Precision Nutrition in Metabolic Syndrome.
    https://link.springer.com/chapter/10.1007/978-981-96-6246-3_13
  3. Moyed Alsaadawe., et al. (2025). From Viral Infection to Malignancy: The Dual Threat of EBV and COVID-19 in Cancer Development.
    https://www.mdpi.com/1999-4915/17/9/1195
  4. Moyed Alsaadawe., et al. (2019). Protein interactome of the deamidase phosphoribosylformylglycinamidine synthetase (PFAS) by LC-MS/MS.
    https://www.sciencedirect.com/science/article/abs/pii/S0006291X19306618
  5. Moyed Alsaadawe., et al. (2022). Prevalence and seasonal pattern of enteric viruses among hospitalized children with acute gastroenteritis in Samawah, Iraq.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC8852632/

Sirinya Sitthirak | Cancer | Excellence in Research Award

Published on by Applied Scientist

Dr. Sirinya Sitthirak | Cancer | Excellence in Research Award

Walailak University | Thailand

Dr. Sirinya Sitthirak is an emerging scientist specializing in cancer genomics, multi-omics integration, and computational biology, with a strong focus on accelerating precision oncology through advanced data analytics. Her research spans cancer genomics, proteomics, phosphoproteomics, metabolomics, microbiome studies, and systems-level multi-omics approaches, allowing her to dissect tumor complexity and uncover biomarkers that drive cancer progression and therapeutic response. She has contributed to impactful research such as predicting cisplatin response in cholangiocarcinoma using chromosome patterns and gene-expression signatures, reflecting her commitment to improving clinical outcomes through translational genomics. Dr. Sitthirak is proficient in genome-wide association studies (GWAS), high-throughput data analysis, and Linux-based bioinformatics workflows using R and Python, enabling her to explore cancer evolution, drug resistance mechanisms, and tumor ecological dynamics. Her scientific engagement is demonstrated through invited oral and poster presentations at prestigious global platforms, including the Cancer Evolution: From Genome to Ecology meeting hosted by Wellcome Connecting Science at the University of Cambridge, the International Conference on Cancer Bioinformatics (ETH Zurich), and the European Association for Cancer Research (EACR) conferences. Dr. Sitthirak has earned multiple competitive honors, including bursaries, travel grants, and international presentation awards, underscoring the significance of her contributions. She is also actively involved in capacity building as an instructor for regional bioinformatics programs, teaching helminth genomics, SARS-CoV-2 bioinformatics, and cancer genome analysis across Asia. Overall, her research integrates multi-omics technologies with computational innovation to advance the understanding of cancer biology and support the development of precision diagnostic and therapeutic strategies.

Profile: Scopus

Featured Publication

Sitthirak, S., [Co-authors]. (2025). Predicting cisplatin response in cholangiocarcinoma patients using chromosome pattern and related gene expression. Scientific Reports.

Daniel Herrero Rivera | Oncology | Best Researcher Award

Published on by Applied Scientist

Dr. Daniel Herrero Rivera | Oncology | Best Researcher Award 

Medical Oncologist | HLA Moncloa University Hospital | Spain

Dr. Daniel Herrero Rivera is a distinguished Spanish medical oncologist currently serving as Médico Especialista en Oncología Médica at the Hospital Universitario HLA Moncloa and ATRYS in Spain. With a solid foundation in clinical oncology and translational research, he has established himself as a promising figure in precision oncology and cancer immunotherapy. Dr. Daniel Herrero Rivera earned his medical degree from the Universidad Complutense de Madrid in 2014, followed by multiple advanced qualifications including a Master’s in Medical Oncology (SEOM certification, 2019), a Master’s in Genomic and Big Data Oncology (2020), and a Ph.D. in Molecular Biology, Biomedicine, and Clinical Research from the Universidad de Sevilla (2023). His scholarly contributions include numerous publications in high-impact journals such as European Urology Oncology, Clinical and Translational Oncology, and Radiotherapy and Oncology. He has co-authored several book chapters and presented research exploring the molecular and clinical aspects of cancer therapy, including gene expression signatures, pharmacogenomics, and immuno-oncology. Dr. Daniel Herrero Rivera’s research project on gene polymorphisms in prostate cancer, funded by Fundación Progreso y Salud, reflects his dedication to improving personalized cancer treatments. With 58 citations across 56 documents, 6 publications, and an H-index of 5, his work demonstrates growing academic influence. His commitment to advancing precision oncology and his multidisciplinary expertise place him among Spain’s emerging medical researchers dedicated to bridging clinical practice and molecular innovation in cancer management.

Profile: Scopus | ORCID | Research Gate

Featured Publication

1. Gonçalves, D., Ocanto, A., Meilán, E., Couñago, F., & et al. (2025). First Spanish experience with stereotactic MR-guided adaptive radiotherapy (SMART) in borderline resectable and locally advanced pancreatic cancer: A prospective study. Biomedicines, 13(2390). MDPI.

2. Herrero Rivera, D., Soriano Segura, M., Prato Varela, J. O., Brygadyr Medvid, Y., & López Martín, J. A. (2025). Complete remission with fourth-line immunotherapy after chemotherapy failure in a lung cancer patient with severe autoimmune disease: An unexpected turn in oncologic management. Cureus, 17(6), e86116.

3. Jiménez, N., Garcia de Herreros, M., Reig, Ò., Mellado, B., & et al. (2024). Development and independent validation of a prognostic gene expression signature based on RB1, PTEN, and TP53 in metastatic hormone-sensitive prostate cancer patients. European Urology Oncology. Elsevier.

4. (2022). Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel. Pharmacogenomics. Future Medicine.

5. López Martín, S., & Herrero Rivera, D. (2020). Assessment of factors associated with the intake of folic acid in the periconceptional period. Journal of Gynecology and Women’s Health, 20(3). Juniper Publishers.

6. (2020). Assessment of prognostic and therapeutic factors in male breast cancer: An observational study of a southwest Spanish single center. Archives of Breast Cancer, 7(4), 155–163.